https://yc-1inhibitor.com/infl....uences-involving-tra
This phase 3, randomized, open-label trial involved assigning patients with lenalidomide-refractory multiple myeloma to either cilta-cel or the physician's preferred effective standard treatment. One to three previous treatment approaches had been administered to each of the affected patients. Progression-free survival was the primary endpoint, focusing on the duration of disease-free existence. A total of 419 patients were subjected to a randomization procedure, 20
Respect!
Kommentar
Delen
